Get the Stockscreener App
26.69
0.82%
-0.22
After Hours:
26.69
Cg Oncology Inc stock is traded at $26.69, with a volume of 758.05K.
It is down -0.82% in the last 24 hours and up +2.65% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$26.91
Open:
$26.475
24h Volume:
758.05K
Relative Volume:
0.63
Market Cap:
$2.03B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-21.01
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+2.10%
1M Performance:
+2.65%
6M Performance:
-11.24%
1Y Performance:
-19.97%
1-Day Range:
$26.18
$27.05
1-Week Range:
$25.14
$28.50
52-Week Range:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.69 | 2.05B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial - Insider Monkey
Building trade automation scripts for CG Oncology Inc.Volume Based Swing Signal Prediction Map - Newser
Comparing CG Oncology Inc. in custom built stock radarsShort-Term Bounce Forecast for Oversold Stocks - Newser
How to interpret RSI for CG Oncology Inc. stockChart Pattern Recognition for Profit Timing - Newser
New Product Launches: Will They Boost CG Oncology Inc. Stock in 2025Capital Protected Stock Selections - Newser
Can CG Oncology Inc. stock recover from recent declineSecure Entry Point Finder with Analysis - Newser
11 Best Future Stocks to Buy Now - Insider Monkey
CG Oncology Soars 10.41% Post Legal Win - AInvest
Options Data Show Bullish Bias in CG Oncology Inc.Early Entry Picks Before News Breakout Reviewed - metal.it
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals By Investing.com - Investing.com South Africa
CG Oncology wins Delaware jury trial against ANI Pharmaceuticals - Investing.com Australia
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals - The Manila Times
CG Oncology Secures Major Legal Victory: Court Rules No 5% Royalties on Promising Bladder Cancer Drug - Stock Titan
Why CG Oncology Inc. stock attracts strong analyst attentionFree Low Risk Equity Screener With Results - Newser
How CG Oncology Inc. stock performs during market volatilityWeekly Setup Summary for Risk Controlled Trades - Newser
Intraday pattern recognizer results for CG Oncology Inc.Free Buy Signal Based on Chart Analysis - Newser
What are the latest earnings results for CG Oncology Inc.Get daily expert analysis on top stocks - jammulinksnews.com
Does CG Oncology Inc. stock perform well during market downturnsPhenomenal capital appreciation - jammulinksnews.com
What is the risk reward ratio of investing in CG Oncology Inc. stockGet real-time updates on market trends - jammulinksnews.com
What are CG Oncology Inc. company’s key revenue driversInvest confidently with real-time market updates - jammulinksnews.com
When is CG Oncology Inc. stock expected to show significant growthTriple-digit wealth increases - jammulinksnews.com
How strong is CG Oncology Inc. company’s balance sheetMaximize gains with professional stock picks - jammulinksnews.com
How does CG Oncology Inc. generate profit in a changing economyUnprecedented growth rates - jammulinksnews.com
Has CG Oncology Inc. Stock Ever Crashed Historical Volatility ReviewHigh Potential Stock Ideas - Newser
Bank of New York Mellon Corp Has $3.61 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
What analysts say about CG Oncology Inc. stockSuperior profit margins - Autocar Professional
How CG Oncology Inc. stock reacts to Fed policy changesHigh-octane financial growth - jammulinksnews.com
Is CG Oncology Inc. stock a growth or value playTremendous wealth creation - jammulinksnews.com
What drives CG Oncology Inc. stock priceTremendous return on equity - PrintWeekIndia
Is CG Oncology Inc. a good long term investmentUnstoppable trading performance - Autocar Professional
CG Oncology Inc. Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):